Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05279092 · ClinicalTrials.gov registry record · Phase 2

Yale Steroid Enhanced Versus Exparel Nerveblock TKA RCT Study

A Phase 2 study of Total Knee Replacement and Knee Arthroplasty, sponsored by Yale University.

Recruiting
Registry status
Phase 2
Development phase
250
Enrollment target
2
Study locations

NCT05279092: Recruiting Phase 2 study of Total Knee Replacement and Knee Arthroplasty, sponsored by Yale University.

NCT05279092 is a Phase 2 study of Total Knee Replacement and Knee Arthroplasty that is actively recruiting participants, run by Yale University. The registered enrollment target is 250 participants, above the 188-participant average among 9 other Total Knee Replacement trials with a reported enrollment target (33% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05279092, a Phase 2 study of Total Knee Replacement and Knee Arthroplasty, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
Phase 2
Development phase
250 participants
Enrollment target
2
Study locations

Study Summary

The objective of this phase 2 study is to investigate the efficacy of Dexamethasone sodium phosphate (DEX) plus Methylprednisolone acetate (MPA) in combination with plain bupivacaine (B) compared with Liposomal Bupivacaine (LB) in combination with plain bupivacaine on post-surgical pain control among patients undergoing unilateral total knee arthroplasty (TKA) to asses if perineural B-DEX-MPA will result in superior analgesia efficacy as compared to B-LB. This study will also assess if perineural B-DEX-MPA results in improved quality of postoperative recovery as compared to B-LB.

Primary Outcome

Average postoperative knee pain scores for the first two postoperative days using Visual analogue scale (VAS) pain score. Score range from 0 (no pain) to 10 (worst pain possible).

Interventions

  • DRUG Bupivacaine-Liposomal Bupivacaine
  • DRUG Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate

Study Locations (2)

Connecticut

  • Yale New Haven Hospital Saint Raphael Campus - New Haven
  • Yale New Haven Hospital York Street Campus - New Haven

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2022-09-08
Est. Completion 2028-03
Phase Phase 2
Yale University

1,492 total trials

What NCT05279092 shows while recruiting

NCT05279092 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 188-participant average among 9 other Total Knee Replacement trials with a reported enrollment target (33% higher).

The record links to 2 conditions, with Total Knee Replacement appearing as the primary indexed condition, and to 2 interventions - of which Bupivacaine-Liposomal Bupivacaine is the first listed.

NCT05279092 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT05279092 about?

NCT05279092 is a clinical study titled "Yale Steroid Enhanced Versus Exparel Nerveblock TKA RCT Study". The objective of this phase 2 study is to investigate the efficacy of Dexamethasone sodium phosphate (DEX) plus Methylprednisolone acetate (MPA) in combination with plain bupivacaine (B) compared with Liposomal Bupivacaine (LB) in combination with plain bupivacaine on post-surgical pain control amon...

What is the current status of trial NCT05279092?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2022-09-08. Estimated completion is 2028-03.

What conditions does trial NCT05279092 study?

This clinical trial studies the following conditions: Total Knee Replacement, Knee Arthroplasty.

What interventions are being tested in trial NCT05279092?

The interventions under investigation include: Bupivacaine-Liposomal Bupivacaine (DRUG), Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate (DRUG).

Who is sponsoring clinical trial NCT05279092?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05279092 being conducted?

This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Total Knee Replacement

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05279092's enrollment target sits among peer trials

250 3rd of 9 higher than 7 of 9 other Total Knee Replacement trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Total Knee Replacement trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05279092, the US trial registry maintained by the National Library of Medicine. NCT05279092 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.